S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ENTA

Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

$17.46
+0.93 (+5.63%)
(As of 03/28/2024 ET)
Today's Range
$16.50
$17.76
50-Day Range
$11.71
$17.46
52-Week Range
$8.08
$41.45
Volume
304,820 shs
Average Volume
278,705 shs
Market Capitalization
$369.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.33

Enanta Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
10.7% Upside
$19.33 Price Target
Short Interest
Bearish
12.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.80mentions of Enanta Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.90) to ($4.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.46 out of 5 stars

Medical Sector

296th out of 938 stocks

Pharmaceutical Preparations Industry

130th out of 425 stocks

ENTA stock logo

About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

ENTA Stock Price History

ENTA Stock News Headlines

Enanta Pharmaceuticals Inc
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
ENTA Enanta Pharmaceuticals, Inc.
ENTA Oct 2024 20.000 call
ENTA Oct 2024 22.500 call
ENTA Oct 2024 10.000 put
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Oppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
Q1 2024 Enanta Pharmaceuticals Inc Earnings Call
Recap: Enanta Pharma Q1 Earnings
Earnings Preview For Enanta Pharma
See More Headlines
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ENTA
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.33
High Stock Price Target
$28.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+9.5%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-133,820,000.00
Net Margins
-187.77%
Pretax Margin
-184.73%

Debt

Sales & Book Value

Annual Sales
$79.20 million
Book Value
$10.29 per share

Miscellaneous

Free Float
18,270,000
Market Cap
$373.69 million
Optionable
Optionable
Beta
0.44
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Jay R. Luly Ph.D. (Age 68)
    President, CEO & Director
    Comp: $1.25M
  • Mr. Paul J. Mellett Jr.Mr. Paul J. Mellett Jr. (Age 69)
    Senior VP of Finance & Administration and CFO
    Comp: $666.84k
  • Dr. Yat Sun Or Ph.D. (Age 72)
    Senior VP of Research & Development and Chief Scientific Officer
    Comp: $729.31k
  • Mr. Nathaniel S. Gardiner J.D. (Age 70)
    Senior VP, General Counsel & Secretary
    Comp: $672.67k
  • Mr. Brendan Luu (Age 49)
    Senior Vice President of Business Development
    Comp: $622.86k
  • Ms. Jennifer Viera
    Senior Director of Investor Relations & Corporate Communications
  • Ms. Tara Lynn Kieffer Ph.D. (Age 46)
    Senior Vice President of New Product Strategy & Development
    Comp: $496.85k
  • Dr. Scott T. Rottinghaus M.D. (Age 50)
    Senior VP & Chief Medical Officer
    Comp: $616.73k

ENTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View ENTA analyst ratings
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price target for 2024?

6 brokerages have issued 12-month price objectives for Enanta Pharmaceuticals' shares. Their ENTA share price targets range from $11.00 to $28.00. On average, they predict the company's stock price to reach $19.33 in the next twelve months. This suggests a possible upside of 10.7% from the stock's current price.
View analysts price targets for ENTA
or view top-rated stocks among Wall Street analysts.

How have ENTA shares performed in 2024?

Enanta Pharmaceuticals' stock was trading at $9.41 at the beginning of the year. Since then, ENTA shares have increased by 85.5% and is now trading at $17.46.
View the best growth stocks for 2024 here
.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,410,000 shares, an increase of 15.3% from the February 29th total of 2,090,000 shares. Based on an average daily volume of 263,300 shares, the days-to-cover ratio is currently 9.2 days. Approximately 12.3% of the shares of the company are short sold.
View Enanta Pharmaceuticals' Short Interest
.

When is Enanta Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ENTA earnings forecast
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings data on Wednesday, February, 7th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.18) by $0.40. The biotechnology company earned $18 million during the quarter, compared to analysts' expectations of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative trailing twelve-month return on equity of 60.38%.

What ETF holds Enanta Pharmaceuticals' stock?

Amplify Treatments, Testing and Advancements ETF holds 5,945 shares of ENTA stock, representing 0.75% of its portfolio.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.75%), Vanguard Group Inc. (8.48%), Vanguard Group Inc. (8.48%), Northern Trust Corp (4.42%), Assenagon Asset Management S.A. (2.77%) and Goldman Sachs Group Inc. (0.88%). Insiders that own company stock include Brendan Luu, Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett, Scott T Rottinghaus, Terry Vance and Yat Sun Or.
View institutional ownership trends
.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENTA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners